EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Research progress on gut microbiota in colorectal cancer immunotherapy

Jing Li, Yingkun Yue, Jiaxin Pan, Fang Liang

Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · 2025

DOI: 10.1016/j.bbcan.2025.189476 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2025. Verfasst von Jing Li und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cancer Rehabilitation, Zhengzhou Central Hospital Affiliated to Zhengzhou University, Zhengzhou 450007, China. Hauptthemen laut MEDLINE: Gastrointestinal Microbiome, Colorectal Neoplasms, Immunotherapy, Immune Checkpoint Inhibitors. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 81 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Immune checkpoint inhibitors (ICIs) have demonstrated significant clinical benefits in treating various malignancies. However, their therapeutic efficacy exhibits considerable interindividual variability in patients with colorectal cancer (CRC). In recent years, growing attention has been focused on the regulatory role of the gut microbiota and its metabolic microenvironment in modulating ICIs responses. This article systematically reviews key advances in understanding how the gut microbiota and its metabolites influence ICIs efficacy. For example: Specific bacterial species (e.g., Lactobacillus paracasei and Fusobacterium nucleatum) may regulate ICIs efficacy by modulating antigen presentation or the tumor immune microenvironment. Microbial metabolites, such as short-chain fatty acids (SCFAs), can enhance immune function and thereby improve ICIs outcomes. Potential microbiome-targeted interventions-including probiotic/prebiotic combinations, optimized antibiotic administration timing, refined fecal microbiota transplantation (FMT) protocols, and engineered synthetic biology-based bacterial therapies-are also discussed. By synthesizing current evidence, this review provides a theoretical foundation for developing novel personalized immunotherapy strategies for CRC, with a focus on microbiome modulation to optimize ICIs treatment efficacy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Gastrointestinal MicrobiomeColorectal NeoplasmsImmunotherapyImmune Checkpoint InhibitorsHumansFecal Microbiota TransplantationTumor MicroenvironmentAnimalsProbiotics

Stichwörter der Autor:innen

Colorectal cancerFecal microbiota transplantationGut microbiotaImmune checkpoint inhibitorsShort-chain fatty acids

Substanzen

Immune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Department of Cancer Rehabilitation, Zhengzhou Central Hospital Affiliated to Zhengzhou University, Zhengzhou 450007, China.
  • Department of Hepatobiliary and Pancreatic Surgery, People's Hospital of Henan University, Zhengzhou 450003, China.
  • Department of Cancer Rehabilitation, Zhengzhou Central Hospital Affiliated to Zhengzhou University, Zhengzhou 450007, China. Electronic address: liangfang@zzu.edu.cn.

Zitieren

APA

Li, J., Yue, Y., Pan, J., & Liang, F. (2025). Research progress on gut microbiota in colorectal cancer immunotherapy. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer. https://doi.org/10.1016/j.bbcan.2025.189476

Vancouver

Li J, Yue Y, Pan J, Liang F. Research progress on gut microbiota in colorectal cancer immunotherapy. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer. 2025. doi:10.1016/j.bbcan.2025.189476

BibTeX
@article{Li2025,
  author = {Li, Jing and Yue, Yingkun and Pan, Jiaxin and Liang, Fang},
  title = {Research progress on gut microbiota in colorectal cancer immunotherapy},
  journal = {Biochimica et Biophysica Acta (BBA) - Reviews on Cancer},
  year = {2025},
  doi = {10.1016/j.bbcan.2025.189476}
}
Kostenlos starten →